Clinical Trial

Pharmacogenomic Contributions to Trihexyphenidyl Biotransformation and Response in Children With Dystonic Cerebral Palsy

Study acronym: TRIKE2
Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This study looks at how a medicine called trihexyphenidyl works in children with dystonic cerebral palsy. The study aims to understand how trihexyphenidyl is broken down and used in the body of pediatric patients and whether this is impacted by a person's genetics. Information from this study will also be used to design future clinical trials.
Protocol Amendment History 5 amendments
This ClinicalTrials.gov record has been amended 5 times since 2024-08-13; most recent amendment 2026-06-19.
Status change: Not Yet Recruiting → Recruiting 2024-09-17
Trial Details
NCT Number NCT06554288
Lead Sponsor Children's Mercy Hospital Kansas City
Collaborators: University of Kansas Medical Center
Conditions Pediatric Disorder, Genetic Predisposition, Dystonia, Secondary, Dystonia, Cerebral Palsy, Dystonic-Rigid, Cerebral Palsy, Dyskinetic, Trihexyphenidyl Adverse Reaction, Pharmacogenomic Drug Interaction
Enrollment 40 participants
Start Date 2024-10-15
Primary Completion 2029-11-30 (estimated)
Study Completion 2029-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-06-24